ReviewNature reviews. Drug discovery2009
Voltage-gated potassium channels as therapeutic targets.
Review in Nature reviews. Drug discovery, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 406 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
406 citing papers in PubMed, 1 synthesis or guideline pooled it.
- KFrontiers in pharmacology · 2026Pooled it
- Effects of the KCNQ (Kv7) Channel Opener Ezogabine on Resting-State Functional Connectivity of Striatal Brain Reward Regions, Depression, and Anhedonia in Major Depressive Disorder: Results From a Randomized Controlled Trial.Biological psychiatry · 2025Trial
- The effect of fampridine on working memory: a randomized controlled trial based on a genome-guided repurposing approach.Molecular psychiatry · 2025Trial
- Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial.The American journal of psychiatry · 2021Trial
- Small Molecule Therapeutic Approaches With a Greater Focus on Hearing Loss: A Review.Health science reports · 2026Article
- Probabilistic mapping of sub-genic intolerance reveals functional and disease-critical protein regions.bioRxiv : the preprint server for biology · 2026Article
- Mechanistical and structural basis of Kv channel inhibition by 4-aminopyridine.bioRxiv : the preprint server for biology · 2026Article
- Potassium channels in cancer: from hallmarks to therapeutic targeting.Journal of physiology and biochemistry · 2026Review
- Article
- Evolutionary Analysis of Vertebrate KCNH Voltage-Gated Potassium Channels and Spatial Expression ofJournal of developmental biology · 2026Article
- Shared genetic architecture and neurobiological pathways of problematic alcohol use and anxiety disorders.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Integrated Screening Cascades for Ion-Channel Drug Discovery: Linking Structure, Electrophysiology, Safety Pharmacology, and Human-Relevant Models.International journal of molecular sciences · 2026Review
- KArchiv der Pharmazie · 2026Review
- Article
- Dual pH- and Concentration-Dependent KJACS Au · 2026Article
- Evolutionary analysis of vertebrate KCNH voltage-gated potassium channels and their expression in zebrafish embryos.bioRxiv : the preprint server for biology · 2026Article
- Distinct mechanisms of inhibition of Kv2 potassium channels by tetraethylammonium and RY785.eLife · 2026Article
- Galangin, a novel Kv7 potassium channel opener, exerts potent antinociceptive effects in multiple chronic pain mouse models.Acta pharmacologica Sinica · 2026Article
- A random-walk-based learning framework to uncover novel gene candidates for Alzheimer's disease therapy.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2026Article
- Wuji Wan ameliorates ulcerative colitis by restoring impaired membrane transport.Frontiers in pharmacology · 2026Article
346 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The human genome encodes 40 voltage-gated K(+) channels (K(V)), which are involved in diverse physiological processes ranging from repolarization of neuronal and cardiac action potentials, to regulating Ca(2+) signalling and cell volume, to driving cellular proliferation and migration. K(V) channels offer tremendous opportunities for the development of new drugs to treat cancer, autoimmune diseases and metabolic, neurological and cardiovascular disorders. This Review discusses pharmacological strategies for targeting K(V) channels with venom peptides, antibodies and small molecules, and highlights recent progress in the preclinical and clinical development of drugs targeting the K(V)1 subfamily, the K(V)7 subfamily (also known as KCNQ), K(V)10.1 (also known as EAG1 and KCNH1) and K(V)11.1 (also known as HERG and KCNH2) channels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.